LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the TD Cowen 46th Annual Health Care Conference in Boston, MA. The Company is scheduled to present on Tuesday, March 3 at 10:30 a.m. Eastern Time. A live webcast of t ...

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]

Core Viewpoint - Teleflex (TFX) reported quarterly earnings of $3.67 per share, exceeding the Zacks Consensus Estimate of $3.38 per share, and showing an increase from $3.49 per share a year ago, representing an earnings surprise of +8.58% [1][2] Financial Performance - The company achieved revenues of $913.02 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.18%, and up from $764.38 million year-over-year [2] - Over the last four quarters, Teleflex has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance and Outlook - Teleflex shares have declined approximately 29.9% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $4.04 for the upcoming quarter and $14.04 for the current fiscal year [7] Industry Context - The Medical - Instruments industry, to which Teleflex belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Teleflex's stock performance [5][6]

Core Viewpoint - U.S. Physical Therapy (USPH) reported quarterly earnings of $0.66 per share, missing the Zacks Consensus Estimate of $0.67 per share, and showing a decline from $0.69 per share a year ago, indicating an earnings surprise of -1.49% [1] Financial Performance - The company posted revenues of $197.13 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.36%, and showing an increase from $168.03 million year-over-year [2] - Over the last four quarters, U.S. Physical Therapy has exceeded consensus revenue estimates four times [2] Stock Performance - U.S. Physical Therapy shares have declined approximately 1.9% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.69 on revenues of $198.26 million, and for the current fiscal year, it is $2.61 on revenues of $773.83 million [7] - The estimate revisions trend for U.S. Physical Therapy was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which U.S. Physical Therapy belongs, is currently ranked in the top 18% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Macro Economic Overview - The US economy shows resilience with growth driven by high-end consumer spending and significant capital expenditures in artificial intelligence [2] - Labor markets are softening, indicating potential for interest rate cuts in the near term [2] Artificial Intelligence Sector - Announced AI ecosystem deals have accelerated, with some viewed as "money good" while others may require significant equity issuances [3] - Concerns exist regarding a potential bubble in AI-related expenditures, drawing parallels to past fiber optic investments [3][4] - Companies in sectors supporting AI, such as quantum computing, are trading at elevated multiples despite limited revenue [4] Capital Markets and Investment Trends - Capital markets are open, benefiting small-cap stocks, while investment banking activity is viewed positively by bank executives [5] - Unusual trading activity around major events is noted as a negative market development [5] Consumer Behavior - High-income households are driving nearly all discretionary spending growth, although signs of a decline are emerging [6] - The housing market remains sluggish with high mortgage rates, but a recent dip may spur increased activity [6] Stock Market Dynamics - There is a notable disconnect between narrative-driven price action and intrinsic value in several market sectors [7] - Companies generating significant cash flow are struggling to attract investment, highlighting a challenging market environment [7] Ethical Investment Strategies - The Ethical S&P 500 Strategy has performed well, up 21.48% year-to-date compared to 24.63% for the S&P 500 [8] - The strategy excludes defense companies, appealing to investors seeking ethical investment options [9] Small & Micro Cap Strategy - The Small Cap Absolute Growth Strategy has exceeded expectations in its first year, focusing on small and micro-cap stocks with growth potential [11] - Notable gains include Rapid Micro Biosystems, Inc, which is up nearly 300% year-to-date [12] Company-Specific Insights - Tile Shop Holdings proposed a delisting at a price below intrinsic value, indicating a need for more home building activity to realize asset value [13] - Portillo's is undergoing leadership changes aimed at improving execution of its strategic vision [16]

Company Performance - Artivion reported quarterly earnings of $0.24 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and up from $0.07 per share a year ago, representing an earnings surprise of +118.18% [1] - The company posted revenues of $112.97 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.36%, compared to $98.02 million in the same quarter last year [2] - Over the last four quarters, Artivion has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Artivion shares have increased approximately 12.9% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $108.75 million, and for the current fiscal year, it is $0.48 on revenues of $429.25 million [7] Industry Outlook - The Medical - Instruments industry, to which Artivion belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Artivion's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Thermo Fisher Scientific reported quarterly earnings of $5.36 per share, exceeding the Zacks Consensus Estimate of $5.22 per share, but slightly down from $5.37 per share a year ago [1] - The earnings surprise for the quarter was +2.68%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - The company posted revenues of $10.86 billion for the quarter, surpassing the Zacks Consensus Estimate by 1.94% and up from $10.54 billion year-over-year [3] Stock Performance - Thermo Fisher shares have declined approximately 17.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.3% [4] - The current Zacks Rank for Thermo Fisher is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $5.53 on revenues of $10.87 billion, and for the current fiscal year, it is $22.34 on revenues of $43.7 billion [8] - The outlook for the Medical - Instruments industry, to which Thermo Fisher belongs, is currently in the bottom 33% of over 250 Zacks industries, which may impact the stock's performance [9]